A novel therapy identified can reduce the risk of advanced cancers in about three-quarters of patients, both adults, and children by targeting a specific genetic mutation.
Results of this multisite phase 1/2 trial have been published in the New England Journal of Medicine. Unlike most cancer therapies, this oral treatment is based on the genetic traits of the tumor and not the organ where the cancer originated.
Physiological Function of Key Cancer Gene may Help Cancer Therapy
New study sheds light on the role of the PTEN gene, which is the second most commonly mutated gene in human cancers.
Advertisement
‘Precision cancer therapy is effective for both adults and children, as it targets only gene mutations and not tumors.’
Tweet it Now
An acquired genetic defect, TRK fusions accelerate cancer cell growth. Larotrectinib is highly selective for inhibiting this process.
Fifty-five patients, ranging from 4 months to 76 years of age, with 17 unique tumor types, were treated with larotrectinib.
Three quarters of patients enrolled responded to therapy and 86% of responding patients remain on study or have undergone curative surgery. No patients discontinued treatment due to drug-related side effects.
![Amino Acid for Brain Cancer Therapy]( "Amino Acid for Brain Cancer Therapy")
Brain tumors are often treated by photodynamic therapy,because of its specificity.It can target very small regions containing cancerous cells while sparing the normal cells around it from damage.
Several pediatric patients that enrolled in the study had infantile fibrosarcoma, a type of cancer that harbors a TRK fusion and is difficult to treat since it responds poorly to chemotherapy.
Radiation therapy is also not a good option since it has devastating long-term effects for young patients.
"This is truly a magic bullet for our patients with TRK-positive cancer," said Leo Mascarenhas M.D, M.S, deputy director of the Children's Center for Cancer and Blood Diseases and director of the Names Family Foundation Early Phase Clinical Trials Program in oncology at Children's Hospital Los Angeles, who helped design the pediatric part of the study.
"In some cases, this cancer can be treated surgically often requiring amputation or another disfiguring surgical procedure. After treating our patient with infantile fibrosarcoma with larotrectinib, the cancer shrunk sufficiently and we were able to surgically remove the tumor while preserving the patient's leg."
This study is part of a noteworthy drug development program. Typically, testing of new therapies in a pediatric population is done after the drug is licensed for adults, if at all. However, larotrectinib was simultaneously studied in children and adults.
A special liquid formulation was developed for administering appropriate doses to very young patients. This early pediatric focus helped to accelerate clinical development by aiding in the rapid accrual of appropriate patients.
The FDA granted larotrectinib breakthrough therapy designation that resulted in an expedited review.
Drugs may qualify as breakthrough therapies when preliminary clinical data indicate that the new treatment offers substantial advantages over existing options for serious or life-threatening diseases.
Source: Eurekalert
Three quarters of patients enrolled responded to therapy and 86% of responding patients remain on study or have undergone curative surgery. No patients discontinued treatment due to drug-related side effects.
Amino Acid for Brain Cancer Therapy
Brain tumors are often treated by photodynamic therapy,because of its specificity.It can target very small regions containing cancerous cells while sparing the normal cells around it from damage.
Advertisement
Several pediatric patients that enrolled in the study had infantile fibrosarcoma, a type of cancer that harbors a TRK fusion and is difficult to treat since it responds poorly to chemotherapy.
Radiation therapy is also not a good option since it has devastating long-term effects for young patients.
"This is truly a magic bullet for our patients with TRK-positive cancer," said Leo Mascarenhas M.D, M.S, deputy director of the Children's Center for Cancer and Blood Diseases and director of the Names Family Foundation Early Phase Clinical Trials Program in oncology at Children's Hospital Los Angeles, who helped design the pediatric part of the study.
"In some cases, this cancer can be treated surgically often requiring amputation or another disfiguring surgical procedure. After treating our patient with infantile fibrosarcoma with larotrectinib, the cancer shrunk sufficiently and we were able to surgically remove the tumor while preserving the patient's leg."
This study is part of a noteworthy drug development program. Typically, testing of new therapies in a pediatric population is done after the drug is licensed for adults, if at all. However, larotrectinib was simultaneously studied in children and adults.
A special liquid formulation was developed for administering appropriate doses to very young patients. This early pediatric focus helped to accelerate clinical development by aiding in the rapid accrual of appropriate patients.
The FDA granted larotrectinib breakthrough therapy designation that resulted in an expedited review.
Drugs may qualify as breakthrough therapies when preliminary clinical data indicate that the new treatment offers substantial advantages over existing options for serious or life-threatening diseases.
Source: Eurekalert
New Targeted Cancer Therapy Identified
Modern cancer therapy aims to develop drugs which can target the altered tumor cells in every patient, without affecting the healthy cells.
Advertisement
 Iridium-based Cancer Therapy Selectively Targets Cancer CellsCancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, says study. | Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News
The new study uncovers the efficacy of fixed-duration combination treatment in patients with high-risk leukemia.
The approvals of pipeline drugs such as momelotinib and Vonjo for myelofibrosis (a rare type of blood cancer) over some time will handle the critical unmet needs.
New study highlights the dual role that blood vessels can play in cancer immunotherapy and eliciting anti-tumor immune responses or even preventing breast cancer spread.
New study evaluated the association between exposure to the chemical agent orange and the development of blood cancer with increased bleeding and blood clot formation.
Study suggests two-year immunotherapy treatment for advanced lung cancer may be reasonable